6:29 PM
 | 
Sep 18, 2013
 |  BC Extra  |  Politics & Policy

PhRMA, BIO, Amgen comment on REMS standardization

The Pharmaceutical Research and Manufacturers of America suggested FDA should use the same REMS templates and tools across products that share "similar risk profiles," starting with the standardization of prescriber tools. PhRMA said the...

Read the full 149 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >